Skip to main content

Treatment-Resistant Major Depressive Disorder

0
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Compass Pathways
Compass PathwaysUK - Cheshire
1 program
PsilocybinPHASE_21 trial
Active Trials
NCT05381974Withdrawn0Est. Jun 2023
Compass Therapeutics
1 program
PsilocybinPHASE_2

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
Compass PathwaysPsilocybin

Clinical Trials (1)

The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDD

Start: Sep 2022Est. completion: Jun 20230
Phase 2Withdrawn

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.